Liver Disease Clinical Trials in Houston

Showing 61-80 of 94 trials

Benign Liver Optimal Core Study (Tissue Acquisition Comparison in Benign Liver Disease)

NCT03245580

The primary purpose of this prospective, randomized, multicenter study is to evaluate and compare the amount and quality of tissue samples yielded in a liver biopsy comparing 2 different techniques of EUS guided CORE liver biopsy for benign disease. The two techniques: "modified Wet suction" and "Slow pull" technique of collecting tissue from a liver biopsy via Endoscopic Ultrasound (EUS).

Liver Diseases

Parkview Health153 participantsStarted Mar 2018

Mobile, Alabama, United States • San Jose, California, United States • Fort Wayne, Indiana, United States +4 more locations

TERMINATEDPhase 2< 1 mile

Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis

NCT03059446

This rollover study will provide open-label treatment with cenicriviroc and will assess the long-term safety of continued treatment with cenicriviroc in participants who participated in either the CENTAUR study 652-2-203 \[NCT02217475\] or the AURORA study \[NCT03028740\].

Nonalcoholic SteatohepatitisLiver CirrhosisNon-alcoholic Fatty Liver Disease

Tobira Therapeutics, Inc.167 participantsStarted Feb 2017

Dothan, Alabama, United States • Phoenix, Arizona, United States • Tucson, Arizona, United States +68 more locations

Benign Liver Optimal Core Study (Tissue Acquisition Comparison in Benign Liver Disease)

Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis

Liver Disease Trials in Other Cities

Losartan for the Treatment of Pediatric NAFLD

Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)

Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children

Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis

A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH

The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis

Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis

Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis

A Self Selected Population Study of Undiagnosed NAFLD and NASH, Using an Echosens FibroScan, in at Risk Populations

A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)

Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH

Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients

An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis

The Patient-Reported Outcomes Project of HCV-TARGET

Non-invasive Methods and Surgical Risk Stratification in Cirrhotics Undergoing Elective Extrahepatic Surgery

Other Conditions in Houston